Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study.
Anderson JE, Kopecky KJ, Willman CL, Head D, O'Donnell MR, Luthardt FW, Norwood TH, Chen IM, Balcerzak SP, Johnson DB, Appelbaum FR. Anderson JE, et al. Among authors: balcerzak sp. Blood. 2002 Dec 1;100(12):3869-76. doi: 10.1182/blood-2001-12-0354. Epub 2002 Aug 1. Blood. 2002. PMID: 12393614 Free article. Clinical Trial.
Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500).
Petersdorf SH, Rankin C, Head DR, Terebelo HR, Willman CL, Balcerzak SP, Karnad AB, Dakhil SR, Appelbaum FR. Petersdorf SH, et al. Among authors: balcerzak sp. Am J Hematol. 2007 Dec;82(12):1056-62. doi: 10.1002/ajh.20994. Am J Hematol. 2007. PMID: 17696203 Free article. Clinical Trial.
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M. Weick JK, et al. Among authors: balcerzak sp. Blood. 1996 Oct 15;88(8):2841-51. Blood. 1996. PMID: 8874180 Free article. Clinical Trial.
Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia--results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and levamisole maintenance.
Morrison FS, Kopecky KJ, Head DR, Athens JW, Balcerzak SP, Gumbart C, Dabich L, Costanzi JJ, Coltman CA, Saiki JH, et al. Morrison FS, et al. Among authors: balcerzak sp. Leukemia. 1992 Jul;6(7):708-14. Leukemia. 1992. PMID: 1625490 Clinical Trial.
211 results